Analysts Set MiMedx Group, Inc. (NASDAQ:MDXG) Target Price at $12.00

MiMedx Group, Inc. (NASDAQ:MDXG) has received an average recommendation of “Buy” from the five ratings firms that are presently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $12.00.

Several equities research analysts have recently weighed in on MDXG shares. StockNews.com raised MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 11th. Cantor Fitzgerald started coverage on MiMedx Group in a research report on Tuesday, July 2nd. They set an “overweight” rating and a $11.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of MiMedx Group in a research report on Wednesday, May 1st.

Institutional Trading of MiMedx Group

Institutional investors have recently modified their holdings of the business. AJOVista LLC purchased a new stake in shares of MiMedx Group in the fourth quarter valued at approximately $25,000. Headlands Technologies LLC purchased a new stake in shares of MiMedx Group in the first quarter valued at approximately $27,000. KMG Fiduciary Partners LLC purchased a new stake in shares of MiMedx Group in the fourth quarter valued at approximately $105,000. Loudon Investment Management LLC purchased a new stake in shares of MiMedx Group in the fourth quarter valued at approximately $105,000. Finally, Entropy Technologies LP purchased a new stake in shares of MiMedx Group in the first quarter valued at approximately $99,000. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

MiMedx Group Price Performance

Shares of NASDAQ MDXG opened at $7.48 on Wednesday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.71 and a current ratio of 3.29. MiMedx Group has a fifty-two week low of $5.57 and a fifty-two week high of $9.27. The firm has a market capitalization of $1.10 billion, a PE ratio of 17.00 and a beta of 1.99. The stock’s 50-day simple moving average is $7.20 and its 200-day simple moving average is $7.49.

MiMedx Group (NASDAQ:MDXG) last issued its earnings results on Tuesday, April 30th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.03. MiMedx Group had a return on equity of 39.42% and a net margin of 18.63%. The business had revenue of $84.71 million for the quarter, compared to analyst estimates of $79.36 million. As a group, equities research analysts forecast that MiMedx Group will post 0.32 EPS for the current fiscal year.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.